New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.
The SynNotch platform had shown prior success with detecting the hepatitis B virus, and the research team wanted to expand on its use for the coronavirus. Moving forward, sentinel cells could be further expanded on for future drug development and therapeutic screenings.
"We demonstrate that these sentinel cells can detect purified Spike protein and a model of infected cells that are expressing Spike, and we show that this sensing approach is portable between different cell types, including primary human T lymphocytes and adherent cells. We suggest that this system, when coupled with appropriate therapeutic payloads, represents a potential next-generation targeted therapeutic against future pathogenic threats."
The study "Sentinel cells enable genetic detection of SARS-CoV-2 Spike protein" is available as a preprint on the bioRxiv* server, while the article undergoes peer review.
SARSNotch combines de novo designed protein binders and SynNotch to detect SARS-CoV-2 Spike. A) Schematic of a sentinel cell, with SynNotch’s customizable sensing, transcription, and output components, and the primary antigen sensors used in this study. B) Schematic of Spike sensing experiment. Sentinel cells expressing No Notch, ACE2- Notch, or LCB1-Notch and a BFP fluorophore downstream of SynNotch activation are incubated with purified SARS-CoV-2 Spike before being assessed for activation via flow cytometry. C) Density estimates of Jurkat sentinel activation showing logBFP fluorescence as a function of μg/ml Spike protein. D) Percent of activated Jurkat cells sentinels plotted as a function of Spike dose. E) Density estimates of T Cell sentinels as a function of μg/ml Spike protein. F) Percent of activated T Cell sentinels plotted as a function of Spike dose. Data points and error bars represent mean and standard deviation of 3 biological replicates.
*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
How they did it
The researchers chose the SynNotch model because its platform allows for swappable antigen-sensing domains — making it adaptable for use viruses beyond SARS-CoV-2.
It is composed of an extracellular sensor domain that would target and recognize a specific epitope, fused to a user-defined cleavable intracellular domain retaining a transcription factor at the cellular membrane. Once the antigen is identified, the transcription factor is cleaved and moves into the nucleus to allow for output expression.
For SARS-CoV-2, they used the (5X)UAS-ybTATA as the transcriptional output and the ACE2 as the extracellular sensor. They also used de novo binders to serve as antigen sensors for the spike protein. Specifically, they screened for short protein sequences bound to the spike protein and from the screening used LCB1 as the antigen sensor.
SARSNotch showed high sensitivity in detecting spike protein
When testing the SARSNotch on pseudoviruses, they found sentinel cells successful in detecting the spike protein alone or when bound to another cell within 24 hours. Detection sensitivity was high with the platform detecting a purified spike protein at 0.3µg/ml.
They also confirmed the platform's versatility with it being able to be used between various cell types, including primary human T lymphocytes and adherent cells. Thus, the platform's application could be used for delivering therapeutics in a live cell-based therapy and in vitro.
There were some unexpected difficulties with using ACE2 as the antigen sensor as it did not provide a detectable signal output in the presence of the spike protein. The researchers suggest this may be due to size limitations in antigen sensors.
SARSNotch does not increase susceptibility to viral infection. A) Experimental schematic, showing that 3 different Luciferase-encoding pseudotyped virus variants were applied to either Jurkat sentinel cells or ACE2 and TMPRSS2- expressing HEK293T cells (293T-Susceptible), which were then assessed for SARSNotch activation and luciferase expression. B) Luciferase activity, normalized within each cell line to the maximum fluorescence from the VSVG infection, as a function of which pseudovirus was applied. Data points and error bars represent mean and 95% confidence interval of 3 biological replicates.
"Perhaps more likely, the 600 amino acid-long ACE2 extracellular domain is between 2 and 3 times the size of the scFvs and nanobodies that have been used as antigen sensors previously, suggesting potential limits on the size of antigen sensors that SynNotch can accommodate."
Given the adequate size of the de novo-designed binder, LCB1, being only 55 amino acids long, there is also the possibility of specific binding geometry needed for SynNotch activation. Future development on SynNotch would require experimenting with novel binders with a wide range of proteins as antigen sensors.
SARSNotch was able to detect the spike protein without increasing the risk of viral infection in sentinel cells. Sentinel cells appeared to not be a target for viral infection, adding strength to the platform.
Future of SARSNotch
There is still much work to be done before sentinel cells can be implemented for cell-based therapeutics in humans. Refining antigen sensors, reducing costs, and increasing the production rate of platforms are a few things that need to be modified in the future.
However, the researchers say that open collaboration from their scientific colleagues in refining the platform could serve as a promising therapy for detecting and neutralizing future viral threats.
*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
SARS-CoV-2 hijacks cholesterol trafficking to fuel infection and evade immune responses